Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker, Thomas; Wiviott, Stephen D; Mosenzon, Ofri; Goodrich, Erica L; Jarolim, Petr; Cahn, Avivit; Bhatt, Deepak; A. Leiter, Lawrence; McGuire, Darren K.; Wilding, John; oleg, averkov; Budaj, Andrzej; Parkhomenko, A.; Ray, Kausik; Gause-Nilsson, Ingrid; Langkilde, A; Fredriksson, Martin; Raz, Itamar; S. Sabatine, Marc; Morrow, David A

doi:10.25376/hra.22203244.v1

jamacardiology_zelniker_2023_br_230001_1677502645.98956 (1).pdf (408.89 kB)

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

journal contribution

posted on 2023-03-02, 15:43 authored by Thomas Zelniker, Stephen D Wiviott, Ofri Mosenzon, Erica L Goodrich, Petr Jarolim, Avivit Cahn, Deepak Bhatt, Lawrence A. Leiter, Darren K. McGuire, John WildingJohn Wilding, averkov oleg, Andrzej Budaj, A. Parkhomenko, Kausik Ray, Ingrid Gause-Nilsson, A Langkilde, Martin Fredriksson, Itamar Raz, Marc S. Sabatine, David A Morrow

In this study, NT-proBNP and hsTnT were associated with MACE in patients with T2D at high risk of atherosclerotic events, and in individuals with high levels of both biomarkers, dapagliflozin was associated with reduced MACE event rates.

History

Grant ID

20SFRN35120087

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

History

Grant ID

Usage metrics

Categories

Keywords

Licence

Exports